Cargando…
Comparative study of CA242 and CA19-9 for the diagnosis of pancreatic cancer.
A comparative study of a new tumour marker, CA242, and CA19-9 was conducted with special reference to their diagnostic usefulness in pancreatic cancer. CA242 showed sensitivity similar to that of CA19-9 for overall cases and early cases (stage I tumour) of pancreatic cancer. For other malignancies,...
Autores principales: | Kawa, S., Tokoo, M., Hasebe, O., Hayashi, K., Imai, H., Oguchi, H., Kiyosawa, K., Furuta, S., Homma, T. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1994
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033368/ https://www.ncbi.nlm.nih.gov/pubmed/8080734 |
Ejemplares similares
-
Comparative study of CA242 and CA19-9 in chronic pancreatitis.
por: Furuya, N., et al.
Publicado: (1996) -
Elevated serum levels of Dupan-2 in pancreatic cancer patients negative for Lewis blood group phenotype.
por: Kawa, S., et al.
Publicado: (1991) -
CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA.
por: Haglund, C., et al.
Publicado: (1994) -
Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer
por: Dong, Dong, et al.
Publicado: (2018) -
Assessment of tumor markers CA 19-9, CEA, CA 125, and CA 242 for the early diagnosis and prognosis prediction of gallbladder cancer
por: Sinha, Seema Rani, et al.
Publicado: (2022)